<?xml version="1.0" encoding="UTF-8"?>
<p>Australia aims to treat around 15 000 to 20 000 hepatitis C patients per year, to reach the WHO target to eliminate viral hepatitis as a major public health threat by 2030. This early commitment to achieving elimination and provide unrestricted treatment access enabled rapid treatment uptake during the first two years of DAA availability.
 <xref rid="liv14222-bib-0090" ref-type="ref">90</xref> Between March 2016 and late 2018, over 70 000 patients (around 30% of all infected Australians) were treated. The proportion of individuals prescribed DAA treatment by general practitioners increased from 8% in March 2016 to 39% in June 2017.
 <xref rid="liv14222-bib-0093" ref-type="ref">93</xref> With the successful implementation of its hepatitis C strategy – a global benchmark for best practice
 <xref rid="liv14222-bib-0094" ref-type="ref">94</xref> – Australia is on track to achieve elimination by 2030.
 <xref rid="liv14222-bib-0095" ref-type="ref">95</xref>
</p>
